New Monoclonal Antibody | Judge Suspends Pfizer's Request | Pfizer Vaccine Extension

New Monoclonal Antibody | Judge Suspends Pfizer's Request | Pfizer Vaccine Extension

FDA just granted an EUA (Feb 11th 2022) for Lily's Bebtelovimab monoclonal antibody for SARS-COV-2. Interestingly this antibody works against Omicron. Let's review the properties. I think this news has the potential to make you happy and cringe at the same time.

Buy me a coffee :-) https://www.buymeacoffee.com/DrMobeenSyed
Become my patron: https://www.patreon.com/mobeensyed?fan_landing=true
Looking to support my educational work? Donate here: https://paypal.me/mobeensyed?locale.x=en_US

#drbeen #koolbeens #COVID

Disclaimer:
This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only.
Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional.

URL list from Friday, Feb. 11 2022

DrBeen: Continuing Medical Education Online | USMLE Prep | CME and CE marketplace | Nurse Practitioner and Physician Assistant Training Programs | Medical Student Training
https://www.drbeen.com/

Coronavirus (COVID-19) Update: FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant | FDA
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibody-treatment-covid-19-retains

Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19 | Eli Lilly and Company
https://investor.lilly.com/news-releases/news-release-details/lillys-bebtelovimab-receives-emergency-use-authorization

A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness - Full Text View - ClinicalTrials.gov
https://clinicaltrials.gov/ct2/show/NCT04634409

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants - PMC
https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8109210/

Sotrovimab | Emergency Use Authorization (EUA) Information for HCPs
https://www.sotrovimab.com/?cc=ps_4FYVU9R0NX1040193&mcm=300000&gclid=Cj0KCQiAr5iQBhCsARIsAPcwROM3aPa6zKyhCkBwtVO-u9OSq66DbyjeMNaqghKjGZXPMaUCD-ZZ-HkaAudhEALw_wcB&gclsrc=aw.ds

Court Documents - Public Health and Medical Professionals for Transparency
https://phmpt.org/court-documents/

Order-February-7-2022.pdf
https://phmpt.org/wp-content/uploads/2022/02/Order-February-7-2022.pdf

CRFs-for-site-1128.pdf
https://phmpt.org/wp-content/uploads/2022/02/CRFs-for-site-1128.pdf

Pfizer Inc. - Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age
https://investors.pfizer.com/Investors/News/news-details/2022/Pfizer-and-BioNTech-Provide-Update-on-Rolling-Submission-for-Emergency-Use-Authorization-of-Their-COVID-19-Vaccine-in-Children-6-Months-Through-4-Years-of-Age/default.aspx